Stifel resumes DexCom stock coverage with Buy rating on 15-day sensor potential
PositiveFinancial Markets

Stifel has resumed coverage of DexCom stock with a Buy rating, highlighting the potential of its 15-day sensor. This is significant as it reflects confidence in DexCom's innovative technology, which could enhance diabetes management for patients. Investors may see this as a positive signal for the company's growth and market position.
— Curated by the World Pulse Now AI Editorial System